Synta gains on ganetespib data
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) gained $1.79 (23%) to $9.41 on Monday after reporting additional interim data for ganetespib in 172 patients with stage IIIB/IV non-small cell lung cancer adenocarcinoma in the open-label Phase IIb portion of the Phase IIb/III GALAXY trial. Median overall survival (OS) has not yet been reached for the small molecule heat shock protein 90 (Hsp90) inhibitor plus docetaxel as second line treatment, compared to 7.4 months in patients receiving docetaxel alone. Compared to docetaxel alone, ganetespib plus docetaxel reduced the risk of death by 31.2% (p=0.183) in the overall population at the interim analysis (n=172; median follow-up of 3.3 months) and 43.2% in patients with at least six months of follow-up (n=77). ...